In the early 2000s, Korea’s largest conglomerates Samsung, LG and SK were all executing massive investment plans in the field of biopharmaceuticals — a highly unfamiliar realm to Koreans at the time.
Despite its fast growth and strong presence in the market, concerns of an SK Biopharmaceuticals bubble are still a big issue. There are five key points to consider in analyzing the company's success.
Alarm bells are going off as the price-earnings ratio of listed biologics and pharmaceutical shares in Korea is now near 100, suggesting that the popular investment category may be in yet another bubble.
SK Biopharmaceuticals rose 160 percent from its offer price on its first day of trade, hitting two stock exchange-imposed limits on the way up. By market capitalization, it is now Korea's 27th largest company, just ahead of
SK Biopharmaceuticals, a wholly owned subsidiary of SK Holdings, has set an all-time record for deposits and the subscription rate in its initial public offering (IPO),
SK Biopharmaceuticals, a wholly-owned subsidiary of SK Holdings, on Tuesday filed for a planned public listing set for June that could raise nearly 1 trillion won ($816 million).
SK Biopharmaceuticals launched its treatment for partial-onset seizures in adults with epilepsy in the U.S. market months after the company earned approval from the U.S. Food and Drug Administration (FDA) late last year.